November 5, 2019 PAI Top-10

BD Announces Results For 2019 Fourth Fiscal Quarter And Full Year; Provides Fiscal 2020 Guidance

FRANKLIN LAKES, N.J., Nov. 5, 2019 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of $4.584 billion for the fourth fiscal quarter ended September 30, 2019.  This represents an increase of 4.1 percent over the prior-year period.  On a comparable, currency-neutral basis, revenues increased 6.2 percent... Read more

October 14, 2019 Clinical Research/Diagn. Licensing, IP, and Legal

BD and Check-Points Receive FDA Clearance for Molecular Screening Test to Detect Antibiotic-Resistant Bacteria

Oct 29, 2019 FRANKLIN LAKES, N.J., and WAGENINGEN, THE NETHERLANDS, October 29, 2019 – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, along with Check-Points Health B.V., announced today that FDA 510(k) clearance was obtained for a molecular screening test for antibiotic-resistant carbapenemase-producing organisms (CPOs) on the fully-automated BD MAX™ System. The BD MAX™ Check-Points... Read more

September 26, 2019 Licensing, IP, and Legal

BD Announces Leadership Succession Plan

  FRANKLIN LAKES, N.J., Sept. 26, 2019 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that Vincent A. Forlenza, chairman and CEO, will retire as CEO on Jan. 28, 2020, following the company’s annual meeting of shareholders. Forlenza will continue on the BD board of directors, serving... Read more

September 18, 2019 Clinical Research/Diagn. M&A, Partnerships

BD partners with global organizations to support diagnostic testing for AMR

Sep 18, 2019 For the third time in five years, Fortune has named BD to its list of companies that are Changing the World , this year recognizing the company for its significant global efforts and investments to combat antimicrobial resistance (AMR) in the areas of infection prevention, diagnostics, surveillance and reporting. Through its decades of experience in collaborating to... Read more

August 6, 2019 PAI Top-10

BD Announces Results For 2019 Third Fiscal Quarter; Reaffirms Fiscal 2019 Guidance

FRANKLIN LAKES, N.J., Aug. 6, 2019 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of $4.350 billion for the third fiscal quarter ended June 30, 2019.  This represents an increase of 1.7 percent over the prior-year period.  On a comparable, currency-neutral basis, revenues increased 5.7 percent... Read more

June 27, 2019 Clinical Research/Diagn. M&A, Partnerships

United States and Indonesia Expand Collaboration to End Tuberculosis

Jun 27, 2019 JAKARTA (June 27, 2019) — Today, the United States Government through the United States Agency for International Development (USAID) and BD (Becton, Dickinson and Company), a U.S.-based global medical technology company, formalized a new partnership to support Indonesia in eliminating tuberculosis (TB) through its National Tuberculosis Program. “Fighting TB with our Indonesian partners... Read more

June 20, 2019 Acad, Gov/Utilities Microscopy

BD Statement on FDA Circulatory System Devices Panel Regarding Paclitaxel-Coated Devices

FRANKLIN LAKES, N.J., June 20, 2019 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today issued the following statement following the U.S. Food and Drug Administration (FDA) Circulatory System Devices Panel of the Medical Devices Advisory Committee meeting related to the potential increase in mortality associated with the use... Read more

June 18, 2019 Clinical Research/Diagn. Product Launch

BD Unveils New Solution for High Throughput Molecular Diagnostic Testing

Automated BD COR™ System Achieves CE-IVD Status; Now Available in Europe Jun 18, 2019 FRANKLIN LAKES, NJ (June 18, 2019) – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the CE-IVDD certification of the BD COR™ System in Europe. The high throughput solution for infectious disease diagnostics sets a new standard... Read more

June 17, 2019 Clinical Research/Diagn. PR/Corporate

BD Announces New Leadership for BD Biosciences

Jun 17, 2019 San Jose, Calif., June 17, 2019 – BD (Becton, Dickinson and Company), a leading global medical technology company, today announced the appointment of Puneet Sarin to worldwide president, BD Biosciences, effective today. In his new role, Puneet will be responsible for driving the global strategic, operational and commercial performance across BD Biosciences while advancing... Read more

June 4, 2019 PR/Corporate

BD Announces Pricing and Upsizing of Tender Offers

FRANKLIN LAKES, N.J., June 4, 2019 /PRNewswire/ — Becton, Dickinson and Company (NYSE: BDX) (the “Company” or “BD“) today announced the consideration payable in connection with its previously announced tender offers to purchase for cash, in the order of priority set forth in the table below, up to the applicable Tender SubCap, if any, of each... Read more